Nsclc

Oncology
22
Pipeline Programs
21
Companies
50
Clinical Trials
7 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
5
9
0
4
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
778%
Monoclonal Antibody
222%
+ 18 programs with unclassified modality

On Market (1)

Approved therapies currently available

Sanofi
CAPRELSAApproved
vandetanib
Sanofi
Kinase Inhibitor [EPC]oral2011

Competitive Landscape

21 companies ranked by most advanced pipeline stage

CT
3 programs
1
1
AnlotinibPhase 4Small Molecule1 trial
sintilimab combined with anlotinibPhase 2Small Molecule1 trial
Anlotinib HydrochlorideN/A1 trial
Active Trials
NCT04007835UnknownEst. Dec 2021
NCT04691388CompletedEst. Dec 2024
NCT03799601UnknownEst. Dec 2020
Sanofi
SanofiPARIS, France
1 program
1
1
CAPRELSA(Vandetanib)Phase 2Small Molecule5 trials
Active Trials
NCT01945762Completed31Est. Jun 2020
NCT01876784Completed238Est. Jan 2022
NCT01661179Completed14Est. Jul 2014
+2 more trials
Galvanize Therapeutics
Galvanize TherapeuticsCA - San Carlos
1 program
1
Aliya Pulsed Electric FieldsPhase 41 trial
Active Trials
NCT05583188TerminatedEst. Mar 2024
H
HutchmedChina - Hong Kong
2 programs
1
1
FruquintinibPhase 3Small Molecule1 trial
FruquintinibPhase 2Small Molecule1 trial
Active Trials
NCT02976116Completed50Est. Jun 2019
NCT02691299Completed527Est. Nov 2018
Pierre Fabre
Pierre FabreFrance - Aignan
1 program
1
Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 GyPhase 31 trial
Active Trials
NCT00683514Completed201
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
QL2107Phase 31 trial
Active Trials
NCT06754644RecruitingEst. Dec 2026
Innogene Kalbiotech
Innogene KalbiotechSingapore - Singapore
1 program
1
RacotumomabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT01460472UnknownEst. Sep 2016
Regeneron
RegeneronTARRYTOWN, NY
2 programs
1
1
CemiplimabPhase 2Monoclonal Antibody1 trial
REGN5093Phase 1/21 trial
Active Trials
NCT04077099Recruiting231Est. Apr 2032
NCT06865339Recruiting76Est. Aug 2027
CSL Behring
CSL BehringIL - Bradley
1 program
1
ALD518Phase 21 trial
Active Trials
NCT00866970Completed124Est. Dec 2009
Bristol Myers Squibb
1 program
1
BMS-986315Phase 21 trial
Active Trials
NCT06094296Terminated1Est. Aug 2024
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
1
BrigatinibPhase 2Small Molecule1 trial
Active Trials
NCT04318938Active Not Recruiting118Est. Apr 2026
Eikon Therapeutics
Eikon TherapeuticsCA - Millbrae
1 program
1
EIK1001Phase 21 trial
Active Trials
NCT06246110Recruiting70Est. Dec 2027
MediLink Therapeutics
MediLink TherapeuticsChina - Suzhou
1 program
1
YL202 should be intravenously infusedPhase 21 trial
Active Trials
NCT06107686RecruitingEst. Nov 2028
InxMed
InxMedChina - Beijing
1 program
1
IN10018Phase 1/21 trial
Active Trials
NCT05994131Recruiting110Est. Jul 2026
IO Biotech
IO BiotechCOPENHAGEN, Denmark
1 program
1
IO102Phase 1/21 trial
Active Trials
NCT03562871Completed109Est. Apr 2022
Jacobio Pharmaceuticals
1 program
1
JAB-8263Phase 1/21 trial
Active Trials
NCT04686682RecruitingEst. Jul 2028
Monte Rosa Therapeutics
1 program
1
Oral MRT-2359Phase 1/21 trial
Active Trials
NCT05546268Active Not RecruitingEst. Nov 2027
Kura Oncology
Kura OncologySAN DIEGO, CA
1 program
1
TipifarnibPhase 1Small Molecule1 trial
Active Trials
NCT05693090Withdrawn0Est. Jul 2027
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
3 programs
De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase InhibitorsN/A1 trial
Epidemiological Study to Describe NSCLC Clinical Management Patterns in Europe. Lung-EPICLINN/A1 trial
Idylla EGFR_IUO/3.20 Mutation TestN/A1 trial
Active Trials
NCT01697163Unknown155Est. Sep 2014
NCT00831909Completed3,513Est. Jul 2010
NCT05959473Withdrawn0Est. Dec 2023
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
GilotrifN/A1 trial
Active Trials
NCT04930133Unknown737Est. Sep 2021
Amgen
AmgenTHOUSAND OAKS, CA
1 program
RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLCN/A1 trial
Active Trials
NCT05273047Unknown458Est. Dec 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Galvanize TherapeuticsAliya Pulsed Electric Fields
Chia Tai TianQing Pharmaceutical GroupAnlotinib
SanofiVandetanib
Qilu PharmaceuticalQL2107
HutchmedFruquintinib
SanofiVandetanib
SanofiVandetanib
Innogene KalbiotechRacotumomab
SanofiVandetanib
SanofiVandetanib
SanofiVandetanib
Pierre FabreOral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy
RegeneronCemiplimab
Eikon TherapeuticsEIK1001
MediLink TherapeuticsYL202 should be intravenously infused

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 7,289 patients across 50 trials

NCT05583188Galvanize TherapeuticsAliya Pulsed Electric Fields

Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC

Start: Feb 2023Est. completion: Mar 2024
Phase 4Terminated
NCT03799601Chia Tai TianQing Pharmaceutical GroupAnlotinib

Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC

Start: Mar 2019Est. completion: Dec 2020
Phase 4Unknown
NCT01496313SanofiVandetanib

To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer

Start: Jun 2012Est. completion: Jul 202481 patients
Phase 4Completed
NCT06754644Qilu PharmaceuticalQL2107

A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC

Start: Jan 2025Est. completion: Dec 2026
Phase 3Recruiting
NCT02691299HutchmedFruquintinib

A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer

Start: Dec 2015Est. completion: Nov 2018527 patients
Phase 3Completed
NCT01876784SanofiVandetanib

Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer

Start: Sep 2013Est. completion: Jan 2022238 patients
Phase 3Completed
NCT01298323SanofiVandetanib

Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment

Start: Feb 2011Est. completion: Mar 2025205 patients
Phase 3Completed
NCT01460472Innogene KalbiotechRacotumomab

Immunotherapy With Racotumomab in Advanced Lung Cancer

Start: Sep 2010Est. completion: Sep 2016
Phase 3Unknown
NCT00410761SanofiVandetanib

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

Start: Nov 2006Est. completion: Jul 2024331 patients
Phase 3Completed
NCT00404924SanofiVandetanib

ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures

Start: Nov 2006Est. completion: Nov 20141,140 patients
Phase 3Completed
NCT00364351SanofiVandetanib

Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy

Start: Aug 2006Est. completion: Nov 20161,574 patients
Phase 3Completed
NCT00683514Pierre FabreOral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy

Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer

Start: Apr 2005201 patients
Phase 3Completed
NCT06865339RegeneronCemiplimab

Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer

Start: Aug 2025Est. completion: Aug 202776 patients
Phase 2Recruiting
NCT06246110Eikon TherapeuticsEIK1001

A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

Start: Feb 2024Est. completion: Dec 202770 patients
Phase 2Recruiting
NCT06107686MediLink TherapeuticsYL202 should be intravenously infused

A Study of YL202 in Selected Patients With Advanced Solid Tumors

Start: Dec 2023Est. completion: Nov 2028
Phase 2Recruiting
NCT06094296Bristol Myers SquibbBMS-986315

A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Start: Nov 2023Est. completion: Aug 20241 patients
Phase 2Terminated
NCT04691388Chia Tai TianQing Pharmaceutical Groupsintilimab combined with anlotinib

A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor

Start: Mar 2021Est. completion: Dec 2024
Phase 2Completed
NCT04318938Heidelberg PharmaBrigatinib

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

Start: Mar 2020Est. completion: Apr 2026118 patients
Phase 2Active Not Recruiting
NCT02976116HutchmedFruquintinib

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

Start: Dec 2016Est. completion: Jun 201950 patients
Phase 2Completed
NCT00752986SanofiVandetanib

ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial

Start: Dec 2008Est. completion: Sep 201339 patients
Phase 2Terminated
NCT00777179SanofiVandetanib

Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy

Start: Oct 2008Est. completion: Dec 2011117 patients
Phase 2Completed
NCT00866970CSL BehringALD518

Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia

Start: Sep 2008Est. completion: Dec 2009124 patients
Phase 2Completed
NCT00686036SanofiVandetanib

Trial Assessing Zactima Against Placebo in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy

Start: May 2008Est. completion: Oct 201017 patients
Phase 2Terminated
NCT00659438SanofiVandetanib

Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer

Start: Feb 2008Est. completion: Jul 201195 patients
Phase 2Completed
NCT00597116SanofiVandetanib

An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma

Start: Dec 2007Est. completion: Jan 201025 patients
Phase 2Terminated
NCT00537095SanofiVandetanib

Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer

Start: Sep 2007Est. completion: Nov 2021164 patients
Phase 2Completed
NCT00508001SanofiVandetanib

Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)

Start: Jul 2007Est. completion: Jun 200967 patients
Phase 2Completed
NCT00454116SanofiVandetanib

A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients

Start: Mar 2007Est. completion: Nov 2009106 patients
Phase 2Completed
NCT00358956SanofiVandetanib

A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

Start: Aug 2006Est. completion: May 201419 patients
Phase 2Completed
NCT00252746SanofiVandetanib

ZD6474 Phase IIa Dose Finding Multicentre Study

Start: Dec 2004Est. completion: Jan 200753 patients
Phase 2Completed
NCT00098345SanofiVandetanib

Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer

Start: Nov 2004Est. completion: Apr 201740 patients
Phase 2Completed
NCT00066313SanofiVandetanib

ZD6474 in Treating Patients With Small Cell Lung Cancer

Start: May 2003Est. completion: Dec 2006
Phase 2Completed
NCT05994131InxMedIN10018

IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

Start: Jul 2023Est. completion: Jul 2026110 patients
Phase 1/2Recruiting
NCT05546268Monte Rosa TherapeuticsOral MRT-2359

Study of Oral MRT-2359 in Selected Cancer Patients

Start: Oct 2022Est. completion: Nov 2027
Phase 1/2Active Not Recruiting
NCT04686682Jacobio PharmaceuticalsJAB-8263

A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors

Start: May 2021Est. completion: Jul 2028
Phase 1/2Recruiting
NCT04077099RegeneronREGN5093

A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

Start: Jan 2020Est. completion: Apr 2032231 patients
Phase 1/2Recruiting
NCT03562871IO BiotechIO102

IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC

Start: Aug 2018Est. completion: Apr 2022109 patients
Phase 1/2Completed
NCT01661179SanofiVandetanib

Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma

Start: Nov 2012Est. completion: Jul 201414 patients
Phase 1/2Completed
NCT00862836SanofiVandetanib

Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)

Start: Apr 2009Est. completion: Sep 201015 patients
Phase 1/2Terminated
NCT05693090Kura OncologyTipifarnib

Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

Start: Feb 2023Est. completion: Jul 20270
Phase 1Withdrawn
NCT01551615SanofiVandetanib

A Phase I Study to Assess the Pharmacokinetics of Metformin When Administered Alone and in Combination With Vandetanib

Start: Mar 2012Est. completion: Jun 201214 patients
Phase 1Completed
NCT01561781SanofiVandetanib

Study in Healthy Volunteers to Assess the Pharmacokinetics (PK) of Digoxin Administered Alone and in Combination With Vandetanib

Start: Mar 2012Est. completion: Jul 201214 patients
Phase 1Completed
NCT01539655SanofiVandetanib

Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib

Start: Feb 2012Est. completion: Sep 201234 patients
Phase 1Completed
NCT00503711SanofiVandetanib

Phase I Chinese PK

Start: Sep 2006Est. completion: Nov 200736 patients
Phase 1Completed
NCT00681798SanofiVandetanib

Dose Escalation Study With Zactima and Chemotherapy in Metastatic Pancreas Carcinoma

Start: Jul 2006Est. completion: Jun 20098 patients
Phase 1Completed
NCT05959473AstraZenecaIdylla EGFR_IUO/3.20 Mutation Test

EGFR_IUO 3.20 Clinical Study Protocol

Start: Sep 2023Est. completion: Dec 20230
N/AWithdrawn
NCT05273047AmgenRW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC

RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC

Start: Mar 2022Est. completion: Dec 2024458 patients
N/AUnknown
NCT04930133Boehringer IngelheimGilotrif

Retrospective Multi-cohort Study of Frontline Afatinib Followed by 2nd Line Therapy Including Osimertinib, Chemotherapy or Other Therapy

Start: Feb 2020Est. completion: Sep 2021737 patients
N/AUnknown
NCT04007835Chia Tai TianQing Pharmaceutical GroupAnlotinib Hydrochloride

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

Start: Jul 2019Est. completion: Dec 2021
N/AUnknown
NCT01945762SanofiVandetanib

Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer

Start: Feb 2014Est. completion: Jun 202031 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
7 actively recruiting trials targeting 7,289 patients
21 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)